J&J to repurchase $5 billion in shares; NICE approves wider statin use;

@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce

@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has announced a $5 billion share repurchase program. Release

> U.K. cost watchdog NICE has approved wider statin use, but critics warn that it could "distort" care. More

> GlaxoSmithKline ($GSK) says a ViiV Healthcare study of a combined maraviroc treatment showed inferior efficacy compared with an alternative combination. Report

> Lundbeck has launched alcohol dependence med Selincro in Spain. Release

> Arena Pharma ($ARNA) and Teva ($TEVA) have inked a marketing and supply deal for obesity drug Belviq in Israel. More

> Stallergenes has acquired Argentina's Alergo Pharma. Release

Medical Device News

@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev

@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2

@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce

@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce

> Intersect, Ocular ready to test the med tech IPO waters. Article

> Smart bandage advances patient monitoring technology. More

> Spinal fusion implants enter market amid growing skepticism from insurers. Article

Biotech News

@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech

@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce

@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- CEO on going public. More | Follow @DamianFierce

@EmilyMFierce: You know you're reading a press release from the U.K. when it has the word "whilst" in it. | Follow @EmilyMFierce

> AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners. Story

> With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia. Article

> Sage takes to the FDA fast track with its lead rare disease drug. News

> Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic. Report

Biotech Research News

> Top 15 NIH-funded disease areas. Report

> Simulated human heart aims to screen drugs for adverse effects. More

> First U.S.-acquired chikungunya case detected. Item

> Simulated human heart aims to screen drugs for adverse effects. Article

> Enzyme may provide new target for Alzheimer's disease. Story

Pharma Manufacturing News

> FedEx to fight charges it was key link in supply chain for illegal drugs. News

> FDA again warns that Texas compounder's products may not be sterile. Item

> GSK, J&J push for genetic engineering of opium. More

> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story

> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article

And Finally... Missouri is the only state in America that has declined to keep a prescription drug database. More (sub. req.)

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.